Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Notes Payables (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Notes Payables for 3 consecutive years, with $35000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Notes Payables fell 99.95% year-over-year to $35000.0, compared with a TTM value of $35000.0 through Sep 2024, down 99.95%, and an annual FY2023 reading of $51.0 million, up 5101200.0% over the prior year.
  • Notes Payables was $35000.0 for Q3 2024 at Oramed Pharmaceuticals, down from $32.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $75.4 million in Q3 2023 and bottomed at $1000.0 in Q2 2022.
  • Average Notes Payables over 3 years is $15.9 million, with a median of $52500.0 recorded in 2022.
  • The sharpest move saw Notes Payables surged 5101200.0% in 2023, then tumbled 99.95% in 2024.
  • Year by year, Notes Payables stood at $1000.0 in 2022, then soared by 5101200.0% to $51.0 million in 2023, then tumbled by 99.93% to $35000.0 in 2024.
  • Business Quant data shows Notes Payables for ORMP at $35000.0 in Q3 2024, $32.0 million in Q1 2024, and $51.0 million in Q4 2023.